Singular Genomics Systems (Singular Genomics Systems) Quality Rank

View and export this data going back to 2021. Start your Free Trial

What is Singular Genomics Systems Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Singular Genomics Systems Quality Rank Related Terms

Thank you for viewing the detailed overview of Singular Genomics Systems's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Singular Genomics Systems (Singular Genomics Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Singular Genomics Systems Inc (NAS:OMIC) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

3010 Science Park Road, San Diego, CA, USA, 92121

Website

https://www.singulargenomics.com

Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.

Executives

Andrew Spaventa	director, 10 percent owner, officer: Chief Executive Officer	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Eli N. Glezer	officer: Chief Scientific Officer	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jyotsna Ghai	officer: Chief Operating Officer	3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Kim P. Kamdar	director	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Marcia Eisenberg	director	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Sam Ropp	officer: Chief Commercial Officer	3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Michael J Pellini	director	222 DUTTON MILL RD, WILLISTOWN PA 19380
Elaine R Mardis	director	301 MERRITT 7, NORWALK CT 06851
James E Flynn	10 percent owner, other: *Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
David Daly	officer: President and Chief Operating	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Vincent Brancaccio	officer: Vice President, HR	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Dalen Meeter	officer: Vice President, Finance	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Daralyn Durie	officer: General Counsel	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jorge Velarde	officer: Senior Vice President	10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
David L Barker	director	9885 TOWNE CENTRE DR, SAN DIEGO CA 92121